Investigational drug · Phase 2
RESP303
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Cystic Fibrosis Bronchiectasis.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "RESP303"
First trial start
2024
Oct 16, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RESP303", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Cystic Fibrosis Bronchiectasis
Approved drugs for the same conditions: Cystic fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "RESP303" as an intervention, largest first.
- Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)Active, not recruiting
Thirty Respiratory LimitedIndustry
NCT06663176 · 60 participants (planned) · Start Oct 16, 2024 · Primary completion Feb 5, 2028
Drug: RESP302; RESP303 · For: Non-Cystic Fibrosis Bronchiectasis
Sites: Kyiv, Ukraine
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-Cystic Fibrosis Bronchiectasis
- HSK31858Phase 33 trials
Haisco Pharmaceutical Group Co., Ltd. · Non-cystic Fibrosis Bronchiectasis, Asthma Bronchiale, Bronchiectasis
- GalvokimigUCB9741Phase 23 trials
UCB · Chronic Obstructive Pulmonary Disease With Chronic Bronchitis, Atopic Dermatitis, Non-cystic Fibrosis Bronchiectasis
- CSL787Phase 21 trial
CSL Behring · Non-cystic Fibrosis Bronchiectasis
- RESP302Phase 21 trial
Thirty Respiratory Limited · Non-Cystic Fibrosis Bronchiectasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.